(H 2 O 2 -induced) stress. This demonstration is important because the destruction of enteric neurons during inflammation depends strongly on forces of oxidative stress that inflammation unleashes (3, 8) . These forces appear in vivo to involve the participation of P2X7 receptor-activated pannexin-1 channels in the neurons, which releases purines (ATP) that stimulate P2Y1 receptors on glia. The activated glia then produce NO, which opens connexin-43 hemichannels that release more purine (ATP) to stimulate P2X7 receptors and execute neurons. Bianco et al. make clear that the neuroprotective effect of prucalopride they observe is specific and depends on the ability of the drug to activate the 5-HT 4 receptor; the 5-HT 4 antagonist GR113808 inhibits prucalopride-mediated neuroprotection. Bianco et al. utilize human cells (neuroblastoma line), neurospheres, and submucosal neurons in biopsy specimens to add the novelty of human relevance to their work. Bianco et al. transcend prior work on 5-HT 4 -mediated neuroprotection in showing that it applies to oxidative stress. It is also significant that the 5-HT 4 agonist they use, prucalopride, is available for therapeutic use in Europe and may soon be cleared for use in the USA. It is a bit surprising, particularly since Bianco et al. studied neurospheres, that they did not devote more attention to 5-HT 4 -mediated neurogenesis. Still, the conclusion of the current report is clear and well supported by data. The utility of a neuroprotective agent in the treatment of inflammatory bowel disease and degenerative disorders of the ENS has not yet been tested. The current article suggests that such testing should soon begin. 
